		(trifluoromethyl)phenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol		2 H) ; 4,47 (td, J=6,1 and 47,5 Hz, 2 H) ; 4,71 (m, 1 H) ; 6,55 (m, 2 H) ; 6,60 (d, J=8,8 Hz, 2 H) ; 6,69 (d, J=8,8 Hz, 2 H) ; 6,71 (s, 1 H) ; 7,20 (dd, J=6,0 and 8,8 Hz, 1 H) ; 7,32 (dt, J=2,8 and 8,8 Hz, 1 H) ; 7,60 (dd, J=2,8 and 9,6 Hz, 1 H) ; 9,41 (s, 1 H)	
62		6-(4-ethoxy-2,5-difluoro-phenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol	A	1H NMR (400 MHz, DMSO-d6, δ ppm): 1,30 (t, J=7,0 Hz, 3 H) ; 1,69 (m, 1 H) ; 1,79 (dm, J=25,3 Hz, 2 H) ; 2,05 (m, 2 H) ; 2,11 to 2,23 (m, 3 H) ; 2,39 (m, 1 H) ; 2,47 (t , J=7,2 Hz, 2 H) ; 2,52 (m , 1 H) ; 2,60 to 2,71 (m, 3 H) ; 2,80 (dd, J=6,4 and 10,5 Hz, 1 H) ; 4,04 (q, J=7,0 Hz, 2 H) ; 4,48 (td, J=6,2 and 47,6 Hz, 2 H) ; 4,74 (m, 1 H) ; 6,57 (s, 2 H) ; 6,62 (d, J=8,9 Hz, 2 H) ; 6,70 (s, 1 H) ; 6,73 (d, J=8,9 Hz, 2 H) ; 6,92 (dd, J=7,4 and 11,2 Hz, 1 H) ; 7,00 (dd, J=7,0 and 11,8 Hz, 1 H) ; 9,41 (s , 1 H)	538
63		5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-methoxy-2-methyl-phenyl)-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid hydrochloride	B	1H NMR (500 MHz, DMSO-d6, δ ppm) : 1,92 to 2,30 (m, 8 H) ; 2,12 (s, 3 H) ; 2,89 (m, 2 H) ; 3,09 to 3,40 (m, 4 H) ; 3,67 (m , 2 H) ; 3,70 (s, 3 H) ; 4,52 (td, J=5,7 and 47,0 Hz, 2 H) ; 4,95 to 5,08 (m, 1 H) ; 6,63 (dd, J=2,6 and 8,5 Hz, 1 H) ; 6,68 (d, J=9,0 Hz, 2 H) ; 6,70 (d, J=2,6 Hz, 1 H) ; 6,73 (d, J=9,0 Hz, 2 H) ; 6,84 (d, J=8,0 Hz, 1 H) ; 6,97 (d, J=8,5 Hz, 1 H) ; 7,84 (dd, J=1,9 and 8,0 Hz, 1 H) ; 7,90 (d, J=1,9 Hz, 1 H) ; 10,30 (s , 0,5 H) ; 10,64 (s , 0,5 H) ; 12,86 (s , 1 H)	530
64		6-(2,4-dimethoxyphenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidi	A	1H NMR (400 MHz, DMSO-d6, δ ppm): 1,68 (m, 1 H) ; 1,79 (dm, J=25,3 Hz, 2 H) ; 1,99 (m, 2 H) ; 2,09 (m, 2 H) ; 2,19 (m, 1 H) ; 2,38 (m, 1 H) ; 2,46 (t, J=7,2 Hz, 2 H) ;	518

CLAIMS

1. A compound of the formula (I):



(I)

wherein:

- R1 and R2 represent independently a hydrogen atom or a deuterium atom;
- R3 represents a hydrogen atom, a -COOH group, a -OH group or a $-OPO(OH)_2$ group;
- R4 represents a hydrogen atom or a fluorine atom;
- R5 represents a hydrogen atom or a -OH group;
- wherein:
    - o at least one of R3 or R5 is different from a hydrogen atom;
    - o when R3 represents a -COOH group, a -OH group or a $-OPO(OH)_2$ group, then R5 represents a hydrogen atom;
    - o when R5 represents a -OH group, then R3 and R4 represent hydrogen atoms;
- R6 is selected from:
    - ▪ a phenyl group or a heteroaryl group comprising 3 to 9 carbon atoms and comprising from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulphur, said phenyl and heteroaryl groups being unsubstituted or substituted with 1 to 3 substituents independently selected from:

    a $(C_1\text{-}C_6)$-alkyl group unsubstituted or substituted with one or more fluorine atoms; a halogen atom; a -OH group; a $(C_1\text{-}C_6)$-alkoxy group unsubstituted or substituted with one or more fluorine atoms; a cyano group; a sulphur group substituted with 5 fluorine atoms or $(C_1\text{-}C_6)$-alkyl groups substituted with two or more fluorine atoms; a sulfonyl-$(C_1\text{-}C_6)$-alkyl group wherein said $(C_1\text{-}C_6)$-alkyl group is unsubstitued or substituted with two or more fluorine atoms; a silane group substituted with 3 $(C_1\text{-}C_6)$-alkyl

groups; an amine group unsubstituted or substituted with one or more (C_1-C_6)-alkyl groups; an amide group unsubstituted or substituted with one or more (C_1-C_6)-alkyl groups; a heterocycloalkyl groups saturated or partially saturated, comprising 3 to 5 carbon atoms and comprising 1 or 2 heteroatoms independently selected from oxygen, nitrogen or sulphur, or a heteroaryl group comprising 2 to 4 carbon atoms and comprising 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur and being unsubstituted or substituted with an oxo group;

- a cycloalkyl group or a heterocycloalkyl group comprising 4 to 9 carbon atoms and comprising 1 or 2 heteroatoms independently selected from oxygen, nitrogen or sulphur, said cycloalkyl or heterocycloalkyl groups being saturated or partially saturated and being unsubstituted or substituted with 1 to 4 substituents independently selected from:

a fluorine atom; a -OH group; a (C_1-C_6)-alkyl group; a -COOR7 group wherein R7 is an (C_1-C_6)-alkyl group; or an oxo group;

or a pharmaceutically acceptable salt thereof.

2. The compound of formula (I) according to claim 1, characterized in that R6 is selected from a phenyl group unsubstituted or substituted with 1 to 3 substituents independently selected from: a (C_1-C_6)-alkyl group unsubstituted or substituted with one or more fluorine atoms; a halogen atom; a-OH group; a (C_1-C_6)-alkoxy group unsubstituted or substituted with one or more fluorine atoms; a cyano group; a sulphur group substituted with 5 fluorine atoms or (C_1-C_6)-alkyl groups substituted with two or more fluorine atoms; a sulfonyl-(C_1-C_6)-alkyl group wherein said (C_1-C_6)-alkyl group is unsubstituted or substituted with two or more fluorine atoms; a silane group substituted with 3 (C_1-C_6)-alkyl groups; an amine group unsubstituted or substituted with one or more (C_1-C_6)-alkyl groups; an amide group unsubstituted or substituted with one or more (C_1-C_6)-alkyl groups; a heterocycloalkyl group saturated or partially saturated, comprising 3 to 5 carbon atoms and comprising 1 or 2 heteroatoms independently selected from oxygen, nitrogen or sulphur, or a heteroaryl group comprising 2 to 4 carbon atoms and comprising 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur and being unsubstituted or substituted with an oxo group;

or a pharmaceutically acceptable salt thereof.

3. The compound of formula (I) according to claim 1 or 2, characterized in that R6 is selected from a phenyl group unsubstituted or substituted with 1 to 3 substituents independently selected from: a methyl group; an ethyl group; an isopropyl group; a

tert-butyl group; a -CHF_2 group; a -CF_3 group; a -CF_2CH_3 group; a chlorine atom; a fluorine atom; a -OH group; a -OCH_3 group; a -OCH_2CH_3 group; a -OCH_2CH_2F group; a -$OCHF_2$ group; a -OCH_2CF_2 group; a -OCF_3 group; a -OCH_2CF_3 group; a cyano group; a -$SCHF_2$ group; a -SCF_3 group; a -SF_5 group; a -SO_2CH_3 group; a -SO_2CF_3 group; a -$Si(CH_3)_3$ group; an oxetan group; a piperidine group; a morpholine group; a pyrrolidine group or a triazolone group;
or a pharmaceutically acceptable salt thereof.

4. The compound of formula (I) according to any of claims 1 to 3, characterized in that R3 is a -COOH group or a -OH group;
or a pharmaceutically acceptable salt thereof.

5. The compound of formula (I) according to any of claims 1 to 4, characterized in that the compound is 5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(1H-indol-5-yl)-8,9-dihydro-7H-benzo[7]annulen-3-ol of the formula,



5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-indolin-5-yl-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(1,2,3,6-tetrahydropyridin-4-yl)-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid of the formula,



5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethoxy)phenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



6-(6-ethoxy-2-fluoro-3-pyridyl)-1-fluoro-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



6-(2-ethoxypyrimidin-5-yl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



[5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-[4-(trifluoromethoxy)phenyl]-8,9-dihydro-7H-benzo[7]annulen-2-yl] dihydrogen phosphate of the formula



or

5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-6-(4-hydroxycyclohexyl)-8,9-dihydro-7H-benzo[7]annulen-2-ol of the formula,



or a pharmaceutically acceptable salt thereof.

6. The compounds selected from the following formulae :



(E)



(F)



(G)



(H)



(J)

wherein R1, R2, R3, R4, R5 and R6 are as defined in formula (I) according to any of claims 1 to 4.

7. A compound of formula (I) according to any of claims 1 to 5, or a pharmaceutically acceptable salt thereof for use as a medicament.

8. A pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

9. A compound of formula (I) according to any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, suitable for use as an inhibitor and degrader of estrogen receptors.

10. A compound of formula (I) according to any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

11. A compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 11, , wherein the cancer is an estrogen receptor dependent cancer.

13. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to any of claim 11 or 12, wherein the cancer is selected from breast, ovarian, endometrial, prostate, uterine, cervical and lung cancer, or a metastasis thereof.

14. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 13, wherein the metastasis is a cerebral metastasis.

15. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 13, wherein the cancer is resistant to anti-hormonal treatment.